APR 10, 2019 10:30 AM PDT

A Sample to Insight Solution for Detection and Classification of Challenging Pathogenic BRCA Mutations

SPONSORED BY: QIAGEN
C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Associate Director Global Product Management NGS, QIAGEN
    Biography
      Dr. Anika Joecker is Associate Director Global Product Management NGS at QIAGEN. She joined CLC bio (now QIAGEN) in 2011 as Senior Bioinformatician/Project & Team Manager and worked since 2013 in product management at QIAGEN - first in Bioinformatics and recently now as product manager of the GeneReader NGS System. Anika Joecker holds a Ph.D. in Biology/Bioinformatics from University of Cologne, Germany, and has worked as Bioinformatics Group Leader at the German Cancer Research Center (Heidelberg, Germany).
    • Principal Genome Scientist, Bioinformatics - Genetic Disease , QIAGEN
      Biography
        Jennifer received a B.S. in Genetics from the University of Connecticut and went on to receive a Ph.D. in Human Genetics at the Johns Hopkins School of Medicine. During her graduate training, she used Ingenuity Pathway Analysis and was so impressed with the tool that she approached QIAGEN for the opportunity to support their bioinformatics portfolio. Currently, she is the lead genome scientist supporting QIAGEN's software solutions for analysis and interpretation of variants implicated in hereditary disease.

      Abstract:

      The BRCA1 and BRCA2 genes epitomize the modern understanding of cancer molecular genetics. Today, identifying germline and somatic mutations in BRCA1/2 has become routine practice, especially for hereditary cancer studies. However, the highly-fragmented nature of traditional sample to insight workflows can make the identification and classification of all pathogenic and actionable variants in BRCA1/2 particularly challenging. In this webinar, we explore these challenges and present solutions for streamlined, standardized, and accurate detection, interpretation, and reporting of challenging BRCA mutations, such as exon-level copy number variants (CNVs), splicing variants, and variants in homopolymer regions. 

      In the first half of the webinar, we will introduce a fully-integrated Sample to Insight NGS clinical research workflow for the detection of BRCA1/2 mutations.  Designed as an integrated part of the GeneReader NGS System, the QIAact BRCA1/2 and the BRCA Advanced Panel leverages unique molecular index (UMI) technology to detect single nucleotide variants (SNVs), exon-level CNVs, even those at low-frequency, ensuring consideration of all variants within the sample. 

      In the second half of the webinar, we will present a concordance study demonstrating the accuracy of QIAGEN Clinical Insight (QCI®), QIAGEN’s clinical decision support software for the interpretation and reporting of NGS data. The study compares QCI’s automated variant classification of over 6,000 BRCA1/2 variants to the human-derived variant classifications from expert panels (the ENIGMA consortium and ClinGen). QCI achieves extremely high concordance (99.6%) and provides automated tiered classifications according to all 28 ACMG guidelines with full transparency to the underlying evidence.  


      Learning Objectives: 

      1. QIAGEN’s GeneReader workflows are pre-optimized sample to insight solutions able to overcome the challenges of a fragmented NGS workflow
      2. The BRCA ½ and the BRCA Advanced Panels coupled with the GeneReader enable comprehensive profiling of mutations within BRCA, including challenging mutations such as large Indels and exon-level CNVs, and with UMI technology, even those of low allele frequency
      3. QCI Interpret as part of the GeneReader solution automates variant classification using all 28 ACMG criteria, while transparently providing the supporting evidence for variant assessment
      4. In compelling concordance study, QCI-Interpret used to automatically classify >6000 BRCA1 and BRCA2 variants, demonstrating the extremely high concordance (99.6%) between automated tiered classification with this clinical decision support platform and classifications by a panel of experts. 


      Show Resources
      You May Also Like
      FEB 26, 2019 09:00 AM PST
      C.E. CREDITS
      FEB 26, 2019 09:00 AM PST
      DATE:  February 26, 2019TIME:   9:00am PST, 12:00pm EST In an era of increasingly high-throughput, large-scale biology, with companies, government and non-prof...
      NOV 15, 2018 10:00 AM PST
      C.E. CREDITS
      NOV 15, 2018 10:00 AM PST
      DATE:  November 15, 2018TIME:  10:00am PT, 1:00pm ET Multiplex fluorescence immunohistochemistry offers a window into the biology of human disease, enabling the ana...
      MAR 26, 2019 02:00 PM PDT
      C.E. CREDITS
      MAR 26, 2019 02:00 PM PDT
      DATE:  March 26, 2019TIME:  2:00pm PDT, 5:00pm EDT  Prostate cancer is the second most common form of cancer in males, affecting one in eight men by the time t...
      NOV 21, 2019 09:00 AM PST
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      C.E. CREDITS
      NOV 21, 2019 09:00 AM PST
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      DATE: November 21, 2019TIME: 9:00am PST, 12:00pm EST Multiple Myeloma is a disease of terminally differentiated plasma cells with the massive production of monoclonal immunoglobu...
      JAN 22, 2019 07:00 AM PST
      C.E. CREDITS
      JAN 22, 2019 07:00 AM PST
      DATE:    January 22, 2019TIME:    07:00am PST, 10:00am EST Molecular diagnostic tests are currently used for infectious disease testing due to t...
      MAY 16, 2019 12:00 PM PDT
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      C.E. CREDITS
      MAY 16, 2019 12:00 PM PDT
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      DATE: May 07, 2019TIME: 10:00 AM PST Mesenchymal stem or stromal cells (MSCs) are a promising resource for cell-based therapies and are being tested in already registered phase...
      Loading Comments...
      Show Resources